CYP19A1 and cancer: Cancer therapeutic regimens with chemotherapeutics, corticosteroids, aromatase inhibitors and androgen deprivation have shown to be significantly associated with fractures and bone loss which can negatively impact the skeletal health of a cancer survivor [24].